Recently, the Hainan Provincial Public Resources Trading Service Center issued the "Notice on the Suspension of Trading of Some Network-Linked Products", which shows that 2,810 proprietary Chinese medicine products from 786 enterprises have suspended trading, and the suspended varieties include Huoxiang Zhengqi Water, Banlan Root Granules, Liuwei Dihuang Pill, Bezoar Detoxification Tablets, etc
.
According to the Notice, these proprietary Chinese medicine products that have been suspended from trading are varieties that have been on the network for one year but have no transaction records, and if they need to resume trading qualifications, they need to submit a demand application from secondary and above medical institutions, and only after review and approval can they resume trading
.
Since the beginning of this year, in addition to Hainan Province, many places have issued notices
on the cancellation of proprietary Chinese medicines and suspension of trading.
For example, on October 20, the Shandong Public Resources Trading Platform issued the Notice on Adjusting the Information of Some Drugs on the Internet, and some drugs, including Tianjin Tongrentang Vascular Rehabilitation Tablets, were suspended from being listed on the Internet
.
On August 19, the Guizhou Provincial Public Resources Trading Network announced the "Notice on Canceling the Qualifications of the Fourth Batch of 107 Drugs in 2022", and a number of proprietary Chinese medicines such as Shuanghuanglian oral liquid, snake gall chuan shell liquid, cold spirit capsules, and banlan root granules were canceled from the network
.
On October 13, the Office of the Leading Group for the Centralized Procurement of Drugs and Medical Consumables for Medical Institutions in Liaoning Province suspended the online procurement
of Xiangdan injection because it received an application from Henan Tongyuan Pharmaceutical.
On July 25, the Gansu Provincial Public Resources Exchange Bureau issued the "Notice of Gansu Province on Publicizing the Application Results of the Hubei Proprietary Chinese Medicine Alliance Centralized Procurement of Unselected Drugs on the Internet", the "Notice" shows that a total of 123 unselected drugs have been declared for the centralized procurement of Hubei Proprietary Chinese Medicine Alliance, of which 12 are planned to be withdrawn from the network and 85 are planned to suspend trading
.
In June, the Anhui Provincial Pharmaceutical Centralized Procurement Platform issued the Notice on Suspension of Yabao Pharmaceutical-related Drug Trading Qualifications, in which 3 specifications of traditional Chinese medicine injections were withdrawn due to the suspension of production, namely coronary heart Ning injection (10 ml) and safflower injection (5 ml, 20 ml).
On May 24, the Guangxi Centralized Procurement Network of Pharmaceuticals and Equipment issued a notice showing that 71 drugs applied for the withdrawal of the network, more than half of which were proprietary Chinese medicines, including many commonly used drugs
such as children's soybean Qingqiao heat granules, Kidney treasure syrup, children's cough syrup, and Chuanbei loquat syrup.
On April 1, the Shanxi Provincial Centralized Bidding and Procurement Network for Pharmaceuticals and Devices issued the "Notice on Publicizing the Revocation of the Platform's Procurement Qualifications of Some Enterprises", which showed that a total of 42 pharmaceutical manufacturers and 77 pharmaceutical regulations applied for the withdrawal of the network, of which more than half were proprietary Chinese medicines
.
.
.
.
.
.
.
Behind the suspension of trading and the cancellation of the hanging network of a large number of proprietary Chinese medicines, the industry believes that it is mainly caused by
the impact of price reduction pressure brought about by the normalization of centralized procurement.
"The price factor is definitely the main reason, if the price of drugs on the network is too high, medical institutions will choose to abandon procurement due to the difficulty of negotiation; Pharmaceutical companies will face profitability challenges if they put drugs at a very low price, so pharmaceutical companies may not sign purchase agreements with medical institutions and choose to abandon the hospital market
.
Some industry insiders said
.
It is reported that some traditional Chinese medicine varieties with a higher proportion of sales in the out-of-hospital market channels, especially oral Chinese medicine products, are sold in the out-of-hospital market than in the in-hospital market, so pharmaceutical companies will not choose to sell the products at low prices after hanging them on the Internet, but more actively embrace the out-of-hospital market
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
